Owen M Wilkins
Overview
Explore the profile of Owen M Wilkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilkins O, Campbell R, Yosufzai Z, Doe V, Soucy S
Brief Bioinform
. 2024 Jul;
25(Supplement_1).
PMID: 39041911
This manuscript describes the development of a resource module that is part of a learning platform named 'NIGMS Sandbox for Cloud-based Learning', https://github.com/NIGMS/NIGMS-Sandbox. The overall genesis of the Sandbox is...
2.
Bagheri M, Mohamed G, Mohamed Saleem M, Ognjenovic N, Lu H, Kolling F, et al.
Cell Rep Med
. 2024 Apr;
5(4):101504.
PMID: 38593809
Targeted therapies have improved outcomes for certain cancer subtypes, but cytotoxic chemotherapy remains a mainstay for triple-negative breast cancer (TNBC). The epithelial-to-mesenchymal transition (EMT) is a developmental program co-opted by...
3.
Preiss N, Kamal Y, Wilkins O, Li C, Kolling 4th F, Trask H, et al.
Life Sci Alliance
. 2023 Jul;
6(9).
PMID: 37414528
Members of the BTB-ZF transcription factor family regulate the immune system. Our laboratory identified that family member Zbtb20 contributes to the differentiation, recall responses, and metabolism of CD8 T cells....
4.
Bagheri M, Mohamed G, Mohamed Saleem M, Ognjenovic N, Lu H, Kolling F, et al.
bioRxiv
. 2023 May;
PMID: 37131809
The epithelial-mesenchymal transition (EMT) is a developmental program co-opted by tumor cells that aids the initiation of the metastatic cascade. Tumor cells that undergo EMT are relatively chemoresistant, and there...
5.
Mohamed G, Mahmood S, Ognjenovic N, Lee M, Wilkins O, Christensen B, et al.
Breast Cancer Res
. 2023 Mar;
25(1):23.
PMID: 36859337
Stratifying breast cancer into specific molecular or histologic subtypes aids in therapeutic decision-making and predicting outcomes; however, these subtypes may not be as distinct as previously thought. Patients with luminal-like,...
6.
Hinds J, Feris E, Wilkins O, Deary L, Wang X, Cole M
PLoS One
. 2022 Aug;
17(8):e0272771.
PMID: 36018850
MYC is one of the most dysregulated oncogenes and is thought to be fundamental to tumor formation and/or maintenance in many cancer types. This dominant pro-tumor activity makes MYC an...
7.
Brown M, Abdollahi B, Wilkins O, Lu H, Chakraborty P, Ognjenovic N, et al.
Sci Adv
. 2022 Aug;
8(31):eabj8002.
PMID: 35921406
The epithelial-to-mesenchymal transition (EMT) is frequently co-opted by cancer cells to enhance migratory and invasive cell traits. It is a key contributor to heterogeneity, chemoresistance, and metastasis in many carcinoma...
8.
Lee M, Brown M, Wilkins O, Pattabiraman D, Christensen B
Epigenomics
. 2022 Apr;
14(9):519-535.
PMID: 35382559
Epithelial-to-mesenchymal transition (EMT) is an early step in the invasion-metastasis cascade, involving progression through intermediate cell states. Due to challenges with isolating intermediate cell states, genome-wide cytosine modifications that define...
9.
Rojas I, Moyer B, Ringelberg C, Wilkins O, Pooler D, Ness D, et al.
Obesity (Silver Spring)
. 2021 Jan;
29(2):337-349.
PMID: 33491319
Objective: The aryl hydrocarbon receptor (AHR) plays a key role in obesity. In vitro studies revealed that the tryptophan metabolite kynurenine (Kyn) activates AHR signaling in cultured hepatocytes. The objective...
10.
Muse M, Titus A, Salas L, Wilkins O, Mullen C, Gregory K, et al.
Epigenetics
. 2020 Apr;
15(10):1093-1106.
PMID: 32255732
Abbreviations: DCIS: ductal carcinoma ; GO: gene ontology; OR: odds ratio; CI: confidence interval; TFBS: transcription factor binding site; LOLA: Locus Overlap Analysis.